KYNB
Kyntra Bio, Inc.
$6.95
-2.11%
2026-05-08
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Key Fundamentals
Forward P/E
-0.69
EPS (TTM)
$-14.40
Revenue Growth (YoY)
-59.3%
Profit Margin
2848.6%
Debt/Equity
437.10
Beta
1.04
Market Cap
$28.7M
Avg Volume (10D)
7K
Recent Breakout Signals
No recent breakout signals detected for KYNB.
Recent Price Range (60 Days)
60D High
$8.99
60D Low
$6.32
Avg Volume
26K
Latest Close
$6.95
Get breakout alerts for KYNB
Sign up for Breakout Scanner to receive daily notifications when KYNB triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Kyntra Bio, Inc. (KYNB) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KYNB daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KYNB operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.